PBMs choose higher-priced Humira, despite biosimilar availability: Study

Pharmaceutical benefit managers are often choosing higher-priced options as biosimilar competitors to Humira hit the market, Becker’s Payer Issues reports. Humira, used to treat rheumatoid arthritis and other conditions, can cost upward of $9,000 a month, according to GoodRx. The drug's first biologic competitor, Amjevita, is offered at two different prices: around $85,500 a year, about 5% less than Humira; and around $40,500 a year, about 55% of Humira's cost.